Skip to main content

Welcome to Janssen Canada

VISIT JANSSEN GLOBAL

Title

Media

13, January, 2021

Toronto

Health Canada Approves IMBRUVICA^® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

22, December, 2020

Toronto

Janssen Announces Health Canada Approval of DARZALEX®* Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma

01, December, 2020

Toronto

Johnson & Johnson Announces the Initiation of a Rolling Submission for its Single-dose Janssen COVID-19 Vaccine Candidate with Health Canada

10, September, 2020

Toronto

Health Canada Approves TREMFYA®* (guselkumab injection), a First-In-Class Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis

31, August, 2020

Toronto

Johnson & Johnson Announces Agreement in Principle with Government of Canada to Supply its COVID-19 Vaccine Candidate

04, August, 2020

Toronto

Janssen Announces Health Canada Approval of DARZALEX®* SC, a New Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma

21, July, 2020

Toronto

^NSPRAVATO® (esketamine) Nasal Spray is Available for Canadian Patients

17, June, 2020

Toronto

Health Canada Approves STELARA® (ustekinumab) for Children with Chronic Moderate to Severe Plaque Psoriasis

22, March, 2020

Toronto

Coronavirus disease (COVID-19) update

23, February, 2020

Toronto

Janssen Receives Health Canada Approval of BALVERSA™ (erdafitinib), the First FGFR Kinase Inhibitor for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations